Reports Q2 revenue $8.8M, consensus $8.12M. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS:
- Stereotaxis (STXS) Q2 Earnings Cheat Sheet
- Stereotaxis receives FDA clearance for MAGiC Sweep catheter
- Stereotaxis Announces $12.5M Stock Offering
- Stereotaxis announces $12.5M registered direct offering
- Promising Prospects for Stereotaxis’ MAGiC Catheter: A Buy Rating Reinforced by Strong Efficacy and Safety